<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of medicines for treatment of adults with generalized anxiety disorder (GAD)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of medicines for treatment of adults with generalized anxiety disorder (GAD)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacology of medicines for treatment of adults with generalized anxiety disorder (GAD)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="12%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Initial daily oral dose*</td> <td class="subtitle1">Daily oral dose range*</td> <td class="subtitle1">Primary metabolism<sup>¶</sup></td> <td class="subtitle1">Effect on metabolism of other drugs<sup>¶</sup></td> <td class="subtitle1">Selected characteristics relevant to treatment of adults with GAD</td> </tr> <tr class="divider_bottom divider_top"> <td colspan="6"><strong>SSRI antidepressants</strong><br/> Applies to all SSRIs: Onset of effect may be delayed 2 to 4 weeks or more. Adverse effects among the SSRIs include: Nausea, diarrhea, insomnia/agitation, somnolence, impaired sexual function, and hyponatremia. Adverse effects of individual agents are presented in a separate table in UpToDate.</td> </tr> <tr> <td class="indent1">Citalopram</td> <td>10 mg</td> <td>10 to 40 mg</td> <td>CYP3A4, 2C19</td> <td>None</td> <td> <ul> <li>Lower risk of insomnia/agitation</li> <li>Few drug interactions</li> <li>Can prolong QT interval with increasing blood levels</li> </ul> </td> </tr> <tr> <td class="indent1">Escitalopram</td> <td>5 to 10 mg</td> <td>10 to 20 mg</td> <td>CYP3A4, 2C19</td> <td>None</td> <td> <ul> <li>Lower risk of insomnia/agitation</li> <li>Few drug interactions</li> </ul> </td> </tr> <tr> <td class="indent1">Sertraline</td> <td>25 to 50 mg</td> <td>50 to 200 mg</td> <td>Limited (minor CYP2C9, 2D6, and 3A4)</td> <td>None</td> <td> <ul> <li>Greater risk of insomnia/agitation</li> <li>More frequent diarrhea and other gastrointestinal complaints</li> </ul> </td> </tr> <tr> <td class="indent1">Paroxetine</td> <td>10 to 20 mg</td> <td>20 to 50 mg</td> <td>CYP2D6</td> <td>Inhibits 2D6</td> <td> <ul> <li>Mildly sedating</li> <li>Weakly anticholinergic</li> <li>Lower risk of insomnia/agitation</li> <li>Withdrawal symptoms if not tapered</li> </ul> </td> </tr> <tr> <td class="indent1">Fluoxetine</td> <td>10 to 20 mg</td> <td>20 to 60 mg</td> <td>CYP2D6, 2C9, and several minor</td> <td>Inhibits CYP2D6, 2C19</td> <td> <ul> <li>Greater risk of insomnia/agitation</li> <li>No withdrawal symptoms if not tapered</li> <li>Takes weeks to reach steady blood levels due to long half-life</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Fluvoxamine</td> <td>50 mg</td> <td>50 to 300 mg</td> <td>CYP1A2, 2D6</td> <td>Inhibits CYP1A2, 2C19</td> <td> <ul> <li>Lower risk of insomnia/agitation</li> <li>Withdrawal symptoms if not tapered</li> <li>Significant drug interactions</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="6"><strong>SNRI antidepressants</strong><br/> Onset of effect and adverse effects of the SNRIs are similar to the SSRIs (refer to above). Adverse effects of individual agents are presented in a separate table in UpToDate.</td> </tr> <tr> <td class="indent1">Duloxetine</td> <td>30 mg</td> <td>60 to 120 mg</td> <td>CYP1A2, 2D6</td> <td>Inhibits CYP2D6</td> <td> <ul> <li>Greater risk of insomnia/agitation</li> <li>Useful for treatment of comorbid painful conditions</li> <li>Withdrawal symptoms if not tapered</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Venlafaxine (extended-release)</td> <td>75 mg</td> <td>75 to 225 mg</td> <td>CYP2D6, 3A4</td> <td>None</td> <td> <ul> <li>Greater risk of insomnia/agitation</li> <li>Increased blood pressure (primarily diastolic) and heart rate with increasing doses</li> <li>Useful for treatment of comorbid painful conditions</li> <li>Few drug interactions</li> <li>Withdrawal symptoms if not tapered</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="6"><strong>Other</strong></td> </tr> <tr> <td class="indent1">Buspirone</td> <td>10 mg in divided doses</td> <td>10 to 60 mg in divided doses</td> <td>CYP3A4</td> <td>None</td> <td> <ul> <li>A nonbenzodiazepine anxiolytic</li> <li>Augmentation choice for partial response to antidepressant</li> <li>Slow onset and modest efficacy</li> <li>Lacks tolerance, dependence, and withdrawal</li> <li>Ineffective for comorbid major depression</li> </ul> </td> </tr> <tr> <td class="indent1">Gabapentin</td> <td>300 mg</td> <td>300 to 2400 mg in divided doses</td> <td>Dependent on renal function for clearance</td> <td>None</td> <td> <ul> <li>A GABA analog calcium-channel modulator antiseizure medication</li> <li>Onset within days of starting treatment</li> <li>Sedation and dizziness</li> <li>Tolerance, dependence, and withdrawal possible</li> </ul> </td> </tr> <tr> <td class="indent1">Pregabalin</td> <td>50 mg in divided doses</td> <td>50 to 300 mg in divided doses</td> <td>Dependent on renal function for clearance</td> <td>None</td> <td> <ul> <li>A GABA analog calcium-channel modulator antiseizure medication</li> <li>Onset within days of starting treatment</li> <li>Approved for treatment of anxiety in some countries (not United States)</li> <li>Sedation and dizziness</li> <li>Tolerance, dependence, and withdrawal possible</li> <li>Schedule V controlled substance in United States</li> <li>Many patients require &gt;150 mg/day, up to 300 mg/day</li> </ul> </td> </tr> <tr> <td class="indent1">Mirtazapine</td> <td>15 mg</td> <td>15 to 60 mg</td> <td>CYP1A2, 2D6, 3A4</td> <td>None</td> <td> <ul> <li>An atypical antidepressant</li> <li>Alternate or augmentation choice for anxiety with insomnia</li> <li>Sedating; notably increases appetite</li> </ul> </td> </tr> <tr> <td class="indent1">Quetiapine</td> <td>25 to 50 mg</td> <td>50 to 300 mg</td> <td>CYP3A4</td> <td>None</td> <td> <ul> <li>An SGA</li> <li>Potential augmentation choice for partial response to antidepressant or alternate as monotherapy</li> <li>Sedation, extrapyramidal effects, weight gain, and metabolic side effects (refer to separate table on SGA adverse effects)</li> <li>Rarely tardive dyskinesia</li> </ul> </td> </tr> <tr> <td class="indent1">Hydroxyzine</td> <td>50 mg at bedtime</td> <td>25 to 50 mg three to four times per day as needed</td> <td>None</td> <td>None</td> <td> <ul> <li>A sedating antihistamine with anxiolytic properties</li> <li>Augmentation option for treatment of insomnia</li> <li>Anticholinergic side-effects with increasing doses</li> </ul> </td> </tr> <tr> <td class="indent1">Imipramine</td> <td>75 mg in divided doses</td> <td>75 to 200 mg in divided doses</td> <td>CYP2C19, 2D6</td> <td>None</td> <td> <ul> <li>A tricyclic antidepressant</li> <li>Anticholinergic side effects</li> <li>Cardiotoxic in overdose</li> <li>May be poorly tolerated relative to SSRI and SNRI antidepressants</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The pharmacology of benzodiazepines used for treatment of adults with generalized anxiety disorder is presented in a separate table in UpToDate.</div><div class="graphic_footnotes">GAD: generalized anxiety disorder; SSRI: selective serotonin reuptake inhibitor; CYP: cytochrome P450; SNRI: serotonin-norepinephrine reuptake inhibitor; GABA: gamma aminobutyric acid; SGA: second-generation antipsychotic.<br/>
* A 50% dose reduction (round to pill strength) and gradual titration is suggested for older adults and individuals sensitive to adverse effects such as nausea, dizziness, headache, and initial insomnia/activation due to antidepressants.<br/>
¶ Data provided on drug metabolism are included to assess the potential for drug interactions. Only strong or moderate effects on other drugs are listed. These classifications are based upon US Food and Drug Administration guidance. Other sources may use a different classification system resulting in some agents being classified differently. Specific drug interactions and management suggestions may be determined by use of <a href="https://www.uptodate.com/drug-interactions?source=responsive_home" target="_blank">Lexi-Interact</a>, the drug interactions program included with UpToDate.</div><div class="graphic_reference">Prepared with data from:
<ol>
<li>World Federation of Societies of Biological Psychiatry (WFSBP), "Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, First Revision," World J Biol Psychiatry. 2008; 9(4):248-312.</li>
<li>Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiat Clin, 2012; 16:77.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 77409 Version 27.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
